Page 1

IRIDEX Source : IRIDEX Corporation August 18 , 2026 16:05 ET Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW , Calif . , Aug. 18 , 2026 ( GLOBE NEWSWIRE ) -- Iridex Corporation ( Nasdaq : IRIX ) , a worldwide leader providing innovative and versatile laser - based medical systems , delivery devices , and accessories for the treatment of glaucoma and retinal diseases , today reported financial results for the second quarter ended July 4 , 2026 . Second Quarter 2026 Financial Highlights • Generated total revenue of $ 12.6 million , compared to $ 13.6 million in the prior year period Cyclo G6Ⓡ product family revenue was $ 3.9 million , representing growth of 19 % year - over - year compared to $ 3.3 million in the prior year period • 。 Sold 17,700 Cyclo G6 probes compared to 13,100 in the prior year period 。 Sold 18 Cyclo G6 Glaucoma Laser Systems compared to 35 in the prior year period • Retina product revenue was $ 6.5 million compared to $ 8.0 million in the prior year period Operating cash flow positive second quarter 2026 • " Our second quarter results were highlighted by the continued momentum in our glaucoma business and operating positive cash flows , " said Patrick Mercer , President and CEO of Iridex . " Cyclo G6 probe volume increased by approximately 35 % , with this lifting G6 product family revenue by 19 % compared to the prior year . This strong performance on the glaucoma side of the business , together with our continued success in controlling costs resulted in positive cash flow in the quarter . Our strong performance in glaucoma was offset by a weaker quarter in retina , due primarily to disruptions impacting the Middle East and reduced sell through in China . As we advance international regulatory approvals , we expect to improve overall retina performance driven by our flagship Pascal platform . " " We are continuing to make significant progress transforming our business , including the transfer of production to lower cost contract manufacturers and relocation of our headquarters to a lower cost facility . We expect this restructuring of the business will help us to achieve sustained long - term profitability " Mr. Mercer continued . Second Quarter 2026 Financial Results Total revenue for the three months ended July 4 , 2026 was $ 12.6 million , representing a decline of 7 % compared to the second quarter of 2025. The decrease in revenue was primarily driven by lower retina product sales , partially offset by continued growth in glaucoma probe sales . Total retina product revenue was $ 6.5 million compared to $ 8.0 million in the prior year period . The decline was isolated to our retina portfolio and driven entirely by temporary , external headwinds — including international commercial transitions and regulatory approval related factors . Total product revenue